STOCK TITAN

Surrozen (SRZN) director awarded 5,550 options at $30.14 exercise price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Surrozen director Mary Haak‑Frendscho received a grant of 5,550 stock options. These Director Stock Options give her the right to buy 5,550 shares of Surrozen common stock at an exercise price of $30.14 per share. The options vest on the anniversary of the May 13, 2026 grant date, as long as she continues serving as a director, and will expire on May 12, 2036 if not exercised.

Positive

  • None.

Negative

  • None.

Insights

Routine director option grant with long-dated vesting and standard service condition.

Director Mary Haak‑Frendscho was granted 5,550 Director Stock Options for Surrozen common stock. The exercise price is $30.14 per share, with a final expiration on May 12, 2036. This is classified as a grant or award, not an open‑market purchase or sale.

The footnote states the options vest on the anniversary of the grant date, contingent on continuous board service. Such time‑based vesting is typical for non‑employee directors and aligns incentives with longer‑term company performance without immediate cash outlay by the company.

After this grant, the filing shows 5,550 derivative securities held, with no additional option positions listed. Future company filings may clarify any subsequent equity awards or exercises that change her overall equity exposure.

Insider Haak-Frendscho Mary
Role null
Type Security Shares Price Value
Grant/Award Director Stock Option (right to buy) 5,550 $0.00 --
Holdings After Transaction: Director Stock Option (right to buy) — 5,550 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 5,550 options Director Stock Option grant on May 13, 2026
Exercise price $30.14 per share Strike price for Director Stock Options
Underlying shares 5,550 shares Common stock underlying granted options
Post-grant derivative holdings 5,550 options Total derivative securities following transaction
Option expiration May 12, 2036 Final expiration date of the grant
Director Stock Option financial
"Director Stock Option (right to buy)"
grant/award acquisition financial
"transaction_action": "grant/award acquisition""
exercise price financial
"conversion_or_exercise_price": "30.1400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"derivativeTransactionCount": 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vesting financial
"The options vest and become exercisable on the anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Haak-Frendscho Mary

(Last)(First)(Middle)
C/O SURROZEN, INC.
171 OYSTER POINT BLVD., SUITE 400

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Surrozen, Inc./DE [ SRZN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (right to buy)$30.1405/13/2026A5,55005/13/2027(1)05/12/2036Common Stock5,550$05,550D
Explanation of Responses:
1. The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.
/s/ Charles Williams, Attorney-in-Fact for Mary Haak-Frendscho05/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Surrozen (SRZN) director Mary Haak-Frendscho receive in this Form 4?

Mary Haak-Frendscho received a grant of 5,550 Director Stock Options. Each option allows her to buy one share of Surrozen common stock at an exercise price of $30.14, subject to vesting and an expiration date in 2036.

What is the exercise price of the Surrozen (SRZN) director stock options?

The exercise price of the director stock options is $30.14 per share. This is the fixed price at which Mary Haak-Frendscho can purchase Surrozen common stock once the options vest, any time before they expire in 2036.

How and when do Mary Haak-Frendscho’s Surrozen (SRZN) options vest?

The options vest and become exercisable on the anniversary of the grant date. Vesting is conditioned on her continuous service as a director, meaning she must remain on Surrozen’s board through that anniversary date for the options to vest.

When do the Surrozen (SRZN) director stock options expire?

The director stock options expire on May 12, 2036. If Mary Haak-Frendscho does not exercise vested options by that date, they will lapse and no longer allow her to purchase Surrozen common stock at the $30.14 exercise price.

Is this Surrozen (SRZN) Form 4 a buy or a grant of options?

This Form 4 reflects a grant of derivative securities, not an open-market buy. The transaction code is A, described as a grant, award, or other acquisition of 5,550 Director Stock Options, giving future purchase rights at a fixed exercise price.